Prof. Matthew Albert is an INSERM director of research and full professor working at Institut Pasteur, where he heads a mixed INSERM / Pasteur Unit. His current positions also include Director of the Department of Immunology; co-‐Director and Founder of The Center for Human Immunology at Institut Pasteur; and Adjunct Faculty at Cochin Hospital. He received his M.D. at Cornell University Medical College and his Ph.D. in Immunology at The Rockefeller University, under the direction of Profs. Robert Darnell and Nina Bhardwaj. He trained in Clinical Pathology, with a focus on transfusion medicine, at The New York Presbyterian Hospital; and was a Clinical Scholar at The Rockefeller University Hospital, under the direction of Prof. Barry Coller.
Albert’s laboratory is centered around a ‘bedside‐to‐bench’ approach to translational research. This has helped him to stay firmly rooted in clinically relevant scientific questions, which has furthered the understanding of disease pathogenesis and helped to establish the proper scientific foundation for the identification of new therapeutic interventions. Specifically, his basic science and clinical research goals focus on the characterization of the cellular and molecular mechanisms underlying the cross‐ priming of tumor and viral‐specific cytolytic T lymphocytes (CTLs). He aims to: define the direct and indirect influence of apoptotic and autophagic cell death on immunity; identify mechanisms of tumor immunity in patients with superficial transitional cell carcinoma of the bladder; and characterize the complex role of type I IFNs and interferon stimulated genes (ISGs) in HCV disease pathogenesis and treatment.
Among the numerous awards, he has received the Burroughs Wellcome Fund Career Award, The Doris Duke Clinical Scientist Development Award and The European Research Council Young Investigator Starting Award. He has successfully launched a commercialized assay for agonist and antagonist forms of CXC10, in partnership with Myriad‐Rules Based Medicine. He is currently coordinating two program projects: (i) Point‐Of‐Care tests to revolutionalize the clinical management of patients infected by Hepatitis C Virus (PoC‐HCV FP7 Consortium); and (ii) LE MILIEU INTÉRIEUR: Defining the genetic and environmental determinants of immune phenotype variance – establishing a path towards personalized medicine.
« Go Back